Education
About Us
Working with TipRanks
Follow Us
Resmed (RMD)
NYSE:RMD
RMD Stock Chart & Stats
$258.31
-$0.23(-0.10%)
At close: 4:00 PM EST
$258.31
-$0.23(-0.10%)
Day’s Range― - ―
52-Week Range$199.92 - $293.81
Previous CloseN/A
Volume178.41K
Average Volume (3M)841.10K
Market Cap
$37.70B
Enterprise Value$37.14B
Total Cash (Recent Filing)$1.42B
Total Debt (Recent Filing)$847.72M
Price to Earnings (P/E)25.5
Beta0.74
Next Earnings
Apr 23, 2026EPS Estimate
2.81Next Dividend Ex-DateN/A
Dividend Yield0.92%
Share Statistics
EPS (TTM)2.81
Shares Outstanding145,966,300
10 Day Avg. Volume947,907
30 Day Avg. Volume841,096
Financial Highlights & Ratios
PEG Ratio0.72
Price to Book (P/B)6.34
Price to Sales (P/S)7.36
P/FCF Ratio22.78
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue6.88
Enterprise Value/Gross Profit11.28
Enterprise Value/Ebitda17.93
Forecast
1Y Price Target
$296.20Price Target Upside14.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)10.95
Revenue Forecast (FY)$5.61B
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Capital AllocationA strong balance sheet and consistent free cash flow provide flexibility for additional share buybacks or targeted acquisitions, reinforcing valuation support.
Demand And Patient AcquisitionIncreased device and mask demand in the Americas, driven by steady resupply, new patient setups, physician training and direct-to-consumer initiatives linked to GLP-1 adoption, supports revenue momentum.
Gross Margin ExpansionGross margin improvement from a more favorable product mix, operational efficiencies and lower component costs underpins stronger earnings and margin guidance.
Bears Say
Competitive Re-entry RiskPotential re-entry of competitors such as Philips/Respironics into the United States flow generator market could pressure market share and pricing for ResMed.
Cost And Expense PressureHigher selling, general and administrative expenses and an elevated effective tax rate have partially offset margin gains, limiting net earnings improvement.
Reimbursement And Competitive BiddingUncertainty around the scope and methodology of the United States Competitive Bidding program could lower reimbursement and average selling prices, creating downside risk to revenue and margins in FY28.
Resmed News
RMD FAQ
What was Resmed’s price range in the past 12 months?
Resmed lowest stock price was $199.92 and its highest was $293.81 in the past 12 months.
What is Resmed’s market cap?
Resmed’s market cap is $37.70B.
When is Resmed’s upcoming earnings report date?
Resmed’s upcoming earnings report date is Apr 23, 2026 which is in 81 days.
How were Resmed’s earnings last quarter?
Resmed released its earnings results on Jan 29, 2026. The company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.746 by $0.064.
Is Resmed overvalued?
According to Wall Street analysts Resmed’s price is currently Undervalued.
Does Resmed pay dividends?
Resmed pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 0.92%. See more information on Resmed dividends here
What is Resmed’s EPS estimate?
Resmed’s EPS estimate is 2.81.
How many shares outstanding does Resmed have?
Resmed has 145,966,300 shares outstanding.
What happened to Resmed’s price movement after its last earnings report?
Resmed reported an EPS of $2.81 in its last earnings report, beating expectations of $2.746. Following the earnings report the stock price went up 0.272%.
Which hedge fund is a major shareholder of Resmed?
Currently, no hedge funds are holding shares in RMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Resmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$296.20 (14.67% Upside)
$296.20 (14.67% Upside)
Blogger Sentiment
Bullish
RMD Sentiment 88%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 30.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.14%
12-Months-Change
Fundamentals
Return on Equity
25.68%
Trailing 12-Months
Asset Growth
19.07%
Trailing 12-Months
Company Description
Resmed
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
RMD Company Deck
RMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple strong operational and financial wins: double-digit headline revenue growth, expanded margins driven by supply-chain productivity, robust device and mask growth, healthy cash generation, continued innovation (new fabric masks, first FDA-cleared AI feature), and a sizable capital return program. Headwinds were present but generally moderate: SG&A growth (partly acquisition-related), a modest tax-rate headwind from global minimum tax, a small restructuring charge, and some lumpiness in ex-U.S. device comps and certain RCS verticals. On balance the highlights materially outweigh the lowlights, reflecting continued execution, margin expansion and strong cash returns to shareholders.View all RMD earnings summariesRMD Revenue Breakdown
51.79% Devices
35.75% Masks and other
12.46% Software as a Service
RMD Stock 12 Month Forecast
Average Price Target
$296.20
▲(14.67% Upside)
Technical Analysis
Baxter International
―
Becton Dickinson
―
Hologic
―
Masimo
―
West Pharmaceutical Services
―
Ownership Overview
0.54% Insiders
17.44% Mutual Funds
0.26% Other Institutional Investors
55.00% Public Companies and Individual Investors